Form 4: Fate Therapeutics CFO Edward J. Dulac III Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Edward J. Dulac III, CFO of Fate Therapeutics, sold 2,447 shares of common stock at $7.77 per share on March 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 4, 2024, Edward J. Dulac III, the Chief Financial Officer of Fate Therapeutics, sold 2,447 shares of the company's common stock.
- The sale was executed at a price of $7.77 per share.
- This transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted by Mr. Dulac on April 5, 2023.
- Following the transaction, Mr. Dulac directly owns 101,479 shares of Fate Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.
Risks
- Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.
Industry Context
Sales by company executives are a normal part of corporate activity. Investors often look to the reasons behind these sales, especially if they are not pre-planned.
Stakeholder Impact
- The stock sale could have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/05/2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 03/04/2024 | Date of the transaction (stock sale) |
| 03/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.